Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06963333

Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance

This study aims to evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability, establish a breath-guided rehabilitation program of intelligent iot and remote home, improve COPD exercise ability, reduce acute exacerbation, and form high-quality clinical evidence.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Zhengzhou, Henan, 450000, China

Location contact

Hailong Zhang, doctor

CONTACT

[email protected]

+86-0371-66248624

About this study

Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease in China. Based on the digital management platform, 548 patients with COPD in stable stage were selected as the research objects. A multi-center, randomized, controlled clinical trial design was adopted to scientifically evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability and reveal its mechanism of action. A breath-guided rehabilitation program based on intelligent iot and remote home was established and promoted to improve exercise ability and reduce acute exacerbation. To form high-quality clinical evidence, and realize tracking management, real-time evaluation and effect evaluation throughout rehabilitation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with COPD in stable stage
  • Patients with grade 2 to 4 lung function
  • Age 40~80 years old
  • Be able to use smart phones, computers and other devices independently or with the help of family members during home training
  • Volunteer for treatment and sign an informed consent form

Exclusion criteria

  • Pregnant or lactating women and patients with recent pregnancy plans
  • Delirious, dementia, all kinds of mental illness
  • Tumor patients who have undergone resection, radiation, and chemotherapy within 5 years
  • Patients with severe osteoarthropathy or osteoporosis, unstable fractures
  • Patients with severe visual impairment that cannot be improved or who have epilepsy or vertigo and cannot use VR devices
  • Patients with progressive neuromuscular disease
  • Patients with pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism and other pulmonary diseases
  • Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.)
  • Patients with severe liver disease (cirrhosis, portal hypertension and bleeding caused by esophageal and gastric varices, etc.) and severe kidney disease (dialysis, kidney transplantation, etc.)
  • Participants who were participating in other clinical trials within 1 month prior to enrollment
  • People who stay in bed for a long time for various reasons

Treatment and study plan

Breathing guided exercise

Behavioral

Breathing guided exercise are divided into six sections: relaxing standing, two fields breathing, regulating lung and kidney, turning side finger, running kidney hall and nourishing qi and collecting gong. Exercise time: 5 days a week, 1 to 2 times a day, a total of 24 weeks.

Flat walking training

Behavioral

Flat walking training can be performed either outdoors or on flat indoor surfaces at a steady pace of 80 to 120 steps per minute for at least 30 minutes each session, raising the heart rate to the target range and maintaining it for over 10 minutes. This should be done 3 to 5 times a week, with 1 to 2 sessions each day, for a total of 24 weeks. The intensity of the exercise is moderate. The target heart rate based on heart rate reserve is calculated as (maximum heart rate during exercise - resting heart rate) × (40-60)% + resting heart rate.

Primary outcomes

  1. 6 Minutes Walking Distance Test (6MWD)

    Time frame: Changes in baseline 6MWD test at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The 6-minute walking distance of the two groups was calculated

Secondary outcomes

  1. Incidence of acute exacerbation

    Time frame: Changes in baseline Incidence of acute exacerbation at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The proportion of patients with ≥1 acute exacerbation in each group during the study period was recorded. If the interval between two acute exacerbations was within 5 days, it was considered as 1 acute exacerbation.

  2. Degree of breathing difficulty

    Time frame: Changes in baseline mMRC scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The modified Medical Research Council dyspnoea scale (mMRC) will be used to assess severity of dyspnea. The mMRC scale is a 4-point (0-4) scale. "0" means no dyspnea perception, "4" means severe dyspnea perception.

  3. Borg dyspnea score

    Time frame: Changes in baseline Borg dyspnea score at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    Borg dyspnea score is a 10-point (0-10) scale based on the severity of dyspnoea. "0" means no dyspnea perception, "10" means most severe dyspnea perception.

  4. The COPD Assessment Test(CAT)

    Time frame: Changes in baseline CAT scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The COPD Assessment Test (CAT) is an 8-item questionnaire that assesses health status in patients with COPD. The questionnaire uses a 0-5 point scale, with higher values indicating a greater impact of COPD on the patient.

  5. Lung function

    Time frame: Changes in baseline Lung function test at weeks 0 and 24 of the treatment.

    Forced Vital Capacity (FVC)、Forced Expiratory Volume in One Second (FEV1) and Percentage of Forced Expiratory Volume in One Second to Predicted Value (FEV1% pred) were mainly used for lung function evaluation.

  6. Anxiety Scale

    Time frame: Changes in baseline SAS scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The Self-Rating Anxiety Scale (SAS) was used to assess the anxiety state of patients. It is a questionnaire consisting of 20 items, with a score range of 1 to 4. The higher the value, the more severe the anxiety state of the patients.

  7. Depression Scale

    Time frame: Changes in baseline SDS scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The Self-Rating Depression Scale (SDS) was used to assess the depressive state of patients. It is a questionnaire consisting of 20 items, with a score range of 1 to 4. The higher the value, the more severe the depressive state of the patients.

  8. Clinical symptom assessment questionnaire (CCQ)

    Time frame: Changes in baseline CCQ scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The Clinical symptom assessment questionnaire (CCQ) is a self-administered questionnaire that measures healthrelated quality of life. It is an 10-item questionnaire on a 0-6 point scale with higher values indicating greater impact of COPD.

  9. St. George's Respiratory Questionnaire (SGRQ)

    Time frame: Changes in baseline SGRQ scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The St. George's Respiratory Questionnaire (SGRQ) scores will be used to evaluate quality of life with a total score of 0-100. The higher scores will indicate the worse outcomes.

  10. The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD)

    Time frame: Changes in baseline mESQ-COPD scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.

  11. The modified COPD Patient-Reported Outcome scale (mCOPD-PRO)

    Time frame: Changes in baseline mCOPD-PRO scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up.

    The modified COPD Patient-Reported Outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.

Study contacts

Contact information is provided by the study sponsor or research team.

Hailong Zhang, doctor

CONTACT

[email protected]

+86-0371-66248624

Jiansheng Li, doctor

CONTACT

[email protected]

+86-0371-66248624

Sponsors and collaborators

Lead sponsor

Henan University of Traditional Chinese Medicine

Other

Collaborators

  • Henan Fantasy Intelligent Technology Co., Ltd
  • Shanxi Bethune Hospital

Registry information

Official study title

Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance: A Multicenter, Randomized, Controlled Clinical Trial

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
May 9, 2025
Registry last updated
May 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.